SHP 465

Drug Profile

SHP 465

Alternative Names: Amphetamine salts (mixed, long acting) - Shire; d,l-Amphetamine and d-amphetamine salts (long acting) - Shire; d,l-Amphetamine and dextroamphetamine salts (long acting) - Shire; d-Amphetamine and d,l-amphetamine salts (long acting) - Shire; Dextroamphetamine and d,l-amphetamine salts (long acting) - Shire; Mydayis; SHP-465; SLI 381; SPD 465; Triple-bead mixed amphetamine salts - Shire

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shire
  • Class Amphetamines
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 06 Nov 2017 Shire plans a phase III trial for Attention deficit hyperactivity disorder (In children; 4-12 years) in November 2017 (NCT03325894)
  • 06 Nov 2017 Shire plans a phase I drug interaction trial for Attention deficit hyperactivity disorder (In children) (NCT03327402)
  • 01 Nov 2017 Shire plans a phase III trial for Attention deficit hyperactivity disorder (In children) in November 2017 (NCT03325881)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top